潤都股份(002923.SZ):產品應用範圍涵蓋消化性潰瘍、高血壓、手術麻醉、解熱鎮痛、抗感染類、糖尿病等多個領域
格隆匯4月9日丨潤都股份(002923.SZ)在投資者互動平台表示,公司是一家集藥物研發、生產、銷售為一體的現代化科技型醫藥企業,主營業務為化學藥製劑、化學原料藥、醫藥中間體的研發、生產和銷售,產品應用範圍涵蓋消化性潰瘍、高血壓、手術麻醉、解熱鎮痛、抗感染類、糖尿病等多個領域。煙鹼為公司近年來拓展的新業務領域,目前已經形成了一定的商業化銷售。公司將根據市場環境,積極調整戰略規劃,爭取更多商業合作機會,以期能更好的回報廣大投資者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.